Navigation Links
Autism Consortium releases data on genes involved in autism to researchers worldwide

BOSTON OCTOBER 22, 2007 The Autism Consortium, a group of researchers, clinicians and families dedicated to radically accelerating research and enhancing clinical care for autism, announced today that it has completed the first genome scan for Autism Spectrum Disorders (ASD) through its Autism Gene Discovery Project and has released the reference data set to a database that autism researchers around the world can use. The scan was conducted using new, high resolution technology developed by Affymetrix on genetic data from more than 3,000 children with ASD and their families.

Todays release of genetic and phenotypic data on autism marks a significant achievement for the autism research community, said Thomas Insel, Ph.D., Director of the National Institute for Mental Health. Progress in finding the causes and cures for autism spectrum disorders rests in large part on improving the rapid access and sharing of data and resources That the Consortium is making the data available to the scientific community even before its own researchers have fully analyzed the information, demonstrates their high degree of commitment to and leadership in advancing autism research.

Along with complementary data generated by Dr. Aravinda Chakravarti at Johns Hopkins and provided to the NIMH this week, these data provide the most detailed look to date at the genetic variation patterns in families with autism.

Mark Daly, PhD, a Consortium member with the Center for Human Genetic Research at Massachusetts General Hospital and a senior associate member of the Broad Institute of Massachusetts Institute of Technology and Harvard, released genetic data from genome wide scans of DNA variation collected from 3,000 individuals who are either affected by autism spectrum disorders, or are family members of individuals with autism. DNA samples for this scan were provided by the Autism Genetic Resource Exchange (AGRE), a program of Autism Speaks, dedicated to accelerating the pace of autism research.

Were releasing raw genotype data so that other qualified researchers can take a look at it even as were still beginning our own analysis, Daly said. Autism Spectrum Disorders are extremely complex and only through collaboration with researchers with many specialized areas of expertise will we gain an understanding of what makes some children susceptible. Thats why we have been committed to providing the data to the research community as fast as we can. The new data will be deposited in the gene bank maintained by AGRE, which, in turn, will make the data available to qualified researchers.

It is really something of a landmark to have both data from his laboratory and mine available to autism researchers at virtually the same time, said Dr. Chakravarti, who collaborated with Dr. Daly for many years. We will each look carefully at the others findings as we continue to search for definitive information about which genes are important in causing autism spectrum disorders.

The prepublication release of such a significant trove of data is a dramatic departure from the traditional less open culture of research science and a landmark achievement for the Consortium and its Autism Gene Discovery Project, the first comprehensive genetic association study to examine the entire human genome related to autism.

The number of individuals diagnosed with autism spectrum disorders has significantly increased in recent years. Although there is some uncertainty about the role that better diagnosis, greater recognition of the disorders, and biological and environmental factors play; there is growing agreement in the research community that genes have a significant role in autism spectrum disorders. The release of the data from this screen is a significant step toward identifying the genes involved in ASD.

Researchers in the Autism Gene Discovery Project conducted the genome wide study using GeneChip microarray technology made by Affymetrix Inc, of Santa Clara, California, in their search for autism spectrum disorder-related genes. The Affymetrix 500K Array offers a comprehensive view of the genome, enabling researchers to analyze 500,000 markers simultaneously and perform whole-genome analyses in large populations. The Affymetrix microarray chips were processed by researchers in the Broad Institute's Genetic Analysis Platform.

These tools enable researchers to search across the entire genome for areas of deletions or duplications of genetic material or for single nucleotide polymorphisms (SNPs), small changes in the DNA sequence. Daly, a statistical geneticist, and his colleagues wrote two mathematical algorithms to analyze the genome scan for specific genes involved in autism spectrum disorders, or for the absence of genes that ought to be present. Among other things, the Autism Consortiums Gene Discovery Group found what they believe may be important new information on the genes involved in autism spectrum disorders. The next step is to conduct an association analysis to determine the role that the genetic variations identified in the scan play in autism spectrum disorders.

According to Daly, the speed at which he collected genome wide data from such a large sample could not have been accomplished without the funding or the collaboration from the Autuism Consortium, which contributed the $1 million needed to complete the project saving the researchers months or years seeking grants. The grant was made possible through a gift from the Anne and Paul Marcus Family Foundation which provided the funds for the Gene Association Study as well as for the purchase of the entire set of samples from AGRE.

Autism spectrum disorders present major challenges for families, communities, and the health care system, said Peter Barrett, president of the Autism Consortium. Our job is to accelerate new ways to diagnose and treat autism spectrum disorders by breaking down barriers. In this case, we are working to foster collaboration between scientists from multiple institutions. Autism spectrum disorders are the focus here, not any single scientific groups accomplishment. What we've shown within a year is that when people work together toward a common goal, we can speed up our understanding of these disorders and move towards better ways to help individuals with autism spectrum disorders and their families.


Contact: Kathryn Morris
The Autism Consortium

Related medicine news :

1. Antibiotics Helps Autism
2. Early diagnosis for autism from blood tests may be possible
3. Latest discovery on Autism
4. Resolving Autism
5. Studying The Causes Of Autism
6. Mercury Pollution Linked To Rise In Autism
7. Early identification of autism possible
8. Autism risks linked to birth factors
9. Autism epidemic is a myth- says a new study
10. Treating Autism More Effectively
11. MMR Vaccination not linked to Autism
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... Libertyville, IL (PRWEB) , ... December 01, 2015 ... ... catheters, keeping their independence is everything. That is why Hollister Incorporated has launched ... excited to offer this next product in the VaPro touch free catheter portfolio,” ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... , ... December 01, 2015 , ... With FCPX ... and with full control over customization, the possibilities are truly endless, all with a ... randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, all ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ... the company will present at the LD Micro Main Event. ... Sunset Boulevard Hotel in Los Angeles, CA. ... present on Thursday, December 3, at 9:00 am Pacific time ... at least 10 minutes prior to the start of the ...
(Date:12/1/2015)... Dec. 1, 2015   MabVax Therapeutics Holdings, Inc ... announces it has filed an Investigational New Drug Application ... for the Company,s lead fully human antibody product HuMab ... MabVax plans to initiate the Phase I clinical trial ... --> The planned Phase I trial will ...
(Date:12/1/2015)... 2015   Craneware, Inc ., the healthcare ... announced the company will showcase a new version ... solution at the American Society for Health-System ... The new features are focused on simplifying and ... managing enterprise-wide pharmacy charges to ensure compliance and ...
Breaking Medicine Technology: